Sulindac sulfde - Induced stimulation of eryptosis

Cellular Physiology and Biochemistry

Volumn 30, Issue 4, 2012, Pages 1072-1082

  Zbidah, Mohanad ^a   Lupescu, Adrian ^a   Yang, Wenting ^a   Bosc, Anastasia ^a   Jilani, Kashif ^a   Shaik, Nazneen ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium; Cell volume; Ceramide; Eryptosis; Phosphatidylserine; Sulindac sulfde

Indexed keywords

CALCIUM ION; CERAMIDE; HEMOGLOBIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; SCATTER FACTOR; SULINDAC SULFIDE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; CALCIUM; DRUG DERIVATIVE; FLUO 3; FLUORESCENT DYE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; XANTHENE DERIVATIVE;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; ERYPTOSIS; ERYTHROCYTE; ERYTHROCYTE VOLUME; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENT ANTIBODY TECHNIQUE; HEMOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; CELL DEATH; CELL SIZE; CYTOLOGY; DRUG EFFECT; METABOLISM;

ANILINE COMPOUNDS; ANNEXIN A5; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CALCIUM; CELL DEATH; CELL SIZE; CERAMIDES; ERYTHROCYTES; FLUORESCENT DYES; HEMOLYSIS; HUMANS; PHOSPHATIDYLSERINES; SULINDAC; XANTHENES;

MLCS; MLOWN;

EID: 84873199275     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341483     Document Type: Article

References (88)

1. Moore RA, Derry S, McQuay HJ: Single dose oral sulindac for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; CD007540.
2. Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC: Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:259-269.
3. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B: Phosphosulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 2011;4:1052-1060.
4. Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, Pickford R, Currey N, Musgrove EA, Kohonen-Corish MR: The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 2011;60:350-360.
5. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA: Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 2010;3:1303-1313.
6. Wang X, Kingsley PJ, Marnett LJ, Eling TE: The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac. Cancer Prev Res (Phila) 2011;4:150-160.
7. Wentz SC, Yip-Schneider MT, Gage EA, Saxena R, Badve S, Schmidt CM: Sulindac prevents carcinogeninduced intrahepatic cholangiocarcinoma formation in vivo. J Surg Res 2009;157:e87-e95.
8. Fujiki H, Suganuma M, Kurusu M, Okabe S, Imayoshi Y, Taniguchi S, Yoshida T: New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat Res 2003;523-524:119-125. (Pubitemid 36293238)
9. Haanen C: Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs 2001;2:677-683. (Pubitemid 32509691)
10. Stepnik M, Ferlinska M, Smok-Pieniazek A, Gradecka-Meesters D, Arkusz J, Stanczyk M: Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. Toxicol In Vitro 2011;25:1075-1084.
11. Lim SJ, Lee E, Lee EH, Kim SY, Cha JH, Choi H, Park W, Choi HK, Ko SH, Kim SH: Docosahexaenoic acid sensitizes colon cancer cells to sulindac sulfide-induced apoptosis. Oncol Rep 2012;27:2023-2030.
12. Liu C, Tsai AL, Chen YC, Fan SC, Huang CH, Wu CC, Chang CH: Facilitation of human osteoblast apoptosis by sulindac and indomethacin under hypoxic injury. J Cell Biochem 2012;113:148-155.
13. Vaish V, Sanyal SN: Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: Exploring NHE-1, intracellular calcium homeostasis and Calpain 9. Biomed Pharmacother 2012;66:116-130.
14. Jakubowska-Mucka A, Sienko J, Zapala L, Wolny R, Lasek W: Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells. Oncol Rep 2012;27:1245-1250.
15. Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH, Yoo DH, Lee SJ, Choe TB, An S, Kwon TJ, Kim JI, Park MJ, Hong SI, Park IC, Rhee CH: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 2006;72:1228-1236. (Pubitemid 44572186)
16. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA: Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 2011;4:1275-1284.
17. Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, Shevde LA, Samant RS, Dean-Colomb W, Piazza GA, Xi Y: Sulindac inhibits tumor cell invasion by suppressing NF-kappaB-mediated transcription of microRNAs. Oncogene 2012; doi: 10.1038/onc.2011.655.
18. Singh R, Cadeddu RP, Frobel J, Wilk CM, Bruns I, Zerbini LF, Prenzel T, Hartwig S, Brunnert D, Schroeder T, Lehr S, Haas R, Czibere A: The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway. Apoptosis 2011;16:889-901.
19. Weidinger C, Krause K, Mueller K, Klagge A, Fuhrer D: FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. J Clin Endocrinol Metab 2011;96:E1361-E1371.
20. Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, Foller M: Eryptosis, a window to systemic disease. Cell Physiol Biochem 2008;22:373-380.
21. 2+ leak of human erythrocytes. Cell Physiol Biochem 2008;21:183-192.
22. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, Schulz E, Munzel T, Lang F: Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J 2009;23:1072-1080.
23. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993;92:520-526. (Pubitemid 23209038)
24. + channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560. (Pubitemid 37429630)
25. Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, Schulze-Osthoff K, Wesselborg S: Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ 2001;8:1197-1206. (Pubitemid 34048474)
26. Lang F, Gulbins E, Lang PA, Zappulla D, Foller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 2010;26:21-28.
27. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F: Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol 2006;290:C244-C253.
28. Bhavsar SK, Bobbala D, Xuan NT, Foller M, Lang F: Stimulation of suicidal erythrocyte death by alpha-lipoic acid. Cell Physiol Biochem 2010;26:859-868.
29. Foller M, Huber SM, Lang F: Erythrocyte programmed cell death. IUBMB Life 2008;60:661-668.
30. Foller M, Mahmud H, Gu S, Wang K, Floride E, Kucherenko Y, Luik S, Laufer S, Lang F: Participation of leukotriene C (4) in the regulation of suicidal erythrocyte death. J Physiol Pharmacol 2009;60:135-143.
31. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB-and PEG-coated gold nanorods on the induction of eryptosis/ erythroptosis in human erythrocytes. Nanotoxicology 2011; [Epub ahead of print].
32. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2011; [Epub ahead of print].
33. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, Thunemann M, Hofmann F, Schuler B, Vogel J, Pichler B, Kasinathan RS, Nicolay JP, Huber SM, Lang F, Feil R: Anemia and splenomegaly in cGKI-deficient mice. Proc Natl Acad Sci USA 2008;105:6771-6776. (Pubitemid 351754582)
34. Bhavsar SK, Gu S, Bobbala D, Lang F: Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem 2011;27:547-556.
35. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2011;302:C644-651.
36. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82. (Pubitemid 29342520)
37. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302. (Pubitemid 29530214)
38. Gallagher PG, Chang SH, Rettig M P, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627. (Pubitemid 36857838)
39. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709. (Pubitemid 350058263)
40. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood 1996;88:1873-1880. (Pubitemid 26307087)
41. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
42. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988. (Pubitemid 40655614)
43. Sanford-Driscoll M, Knodel LC: Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. Drug Intell Clin Pharm 1986;20:925-934. (Pubitemid 17227916)
44. Henrich WL, Brater DC, Campbell WB: Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage. Kidney Int 1986;29:484-489. (Pubitemid 16129058)
45. Davies NM, Watson MS: Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 1997;32:437-459. (Pubitemid 27243647)
46. Brand VB, Sandu CD, Duranton C, Tanneur V, Lang KS, Huber SM, Lang F: Dependence of Plasmodium falciparum in vitro growth on the cation permeability of the human host erythrocyte. Cell Physiol Biochem 2003;13:347-356. (Pubitemid 37465150)
47. Bookchin RM, Ortiz OE, Lew VL: Activation of calcium-dependent potassium channels in deoxygenated sickled red cells. Prog Clin Biol Res 1987;240:193-200.
48. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E, Haussinger D: Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998;78:247-306. (Pubitemid 28070981)
49. Bratosin D, Estaquier J, Petit F, Arnoult D, Quatannens B, Tissier JP, Slomianny C, Sartiaux C, Alonso C, Huart JJ, Montreuil J, Ameisen JC: Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ 2001;8:1143-1156. (Pubitemid 34048470)
50. Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM: Cation channels trigger apoptotic death of erythrocytes. Cell Death Differ 2003;10:249-256. (Pubitemid 36553467)
51. Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004;11:231-243. (Pubitemid 38159647)
52. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010;26:9-20.
53. Dhami R, He X, Schuchman EH: Acid sphingomyelinase deficiency attenuates bleomycin-induced lung inflammation and fibrosis in mice. Cell Physiol Biochem 2010;26:749-760.
54. Becker KA, Grassme H, Zhang Y, Gulbins E: Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell Physiol Biochem 2010;26:57-66.
55. Kuebler WM, Yang Y, Samapati R, Uhlig S: Vascular barrier regulation by PAF, ceramide, caveolae, and NO - an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem 2010;26:29-40.
56. Li X, Becker KA, Zhang Y: Ceramide in redox signaling and cardiovascular diseases. Cell Physiol Biochem 2010;26:41-48.
57. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
58. Walter S, Fassbender K: Spingolipids in Multiple Sclerosis. Cell Physiol Biochem 2010;26:49-56.
59. Arboleda G, Huang TJ, Waters C, Verkhratsky A, Fernyhough P, Gibson RM: Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci 2007;25:3030-3038. (Pubitemid 46888810)
60. De La Monte SM: Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-481.
61. Tong M, Neusner A, Longato L, Lawton M, Wands JR, De La Monte SM: Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis 2009;17:827-844.
62. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH: Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007;56:1210-1218. (Pubitemid 46715599)
63. Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, Raz I, Ilan Y: Betaglycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 2009;296:E72-E78.
64. Holland WL, Summers SA: Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381-402. (Pubitemid 351831506)
65. Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, Lang F, Wieder T, Bosman GJ: The impact of erythrocyte age on eryptosis. Br J Haematol 2012;157:606-614.
66. Felder KM, Hoelzle K, Ritzmann M, Kilchling T, Schiele D, Heinritzi K, Groebel K, Hoelzle LE: Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Cell Physiol Biochem 2011;27:557-564.
67. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK Activation and Function following Osmotic Shock of Erythrocytes. Cell Physiol Biochem 2011;28:1279-1286.
68. Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupec R, Rodemann HP, Ghoreschi K, Rocken M, Schaller M, Lang F, Wieder T: The NFκB Pathway Inhibitors Bay 11-7082 and Parthenolide Induce Programmed Cell Death in Anucleated Erythrocytes. Cell Physiol Biochem 2011;27:45-54.
69. Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F: Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem 2011;28:347-354.
70. Nguyen DB, Wagner-Britz L, Maia S, Steffen P, Wagner C, Kaestner L, Bernhardt I: Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol Biochem 2011;28:847-856.
71. Qadri SM, Kucherenko Y, Zelenak C, Jilani K, Lang E, Lang F: Dicoumarol Activates Ca-permeable Cation Channels Triggering Erythrocyte Cell Membrane Scrambling. Cell Physiol Biochem 2011;28:857-864.
72. Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K, Lang F: Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cell Physiol Biochem 2011;28:339-346.
73. Bhavsar SK, Eberhard M, Bobbala D, Lang F: Monensin induced suicidal erythrocyte death. Cell Physiol Biochem 2010;25:745-752.
74. Braun M, Foller M, Gulbins E, Lang F: Eryptosis triggered by bismuth. Biometals 2009;22:453-460.
75. Eberhard M, Ferlinz K, Alizzi K, Cacciato PM, Faggio C, Foller M, Lang F: FTY720-induced suicidal erythrocyte death. Cell Physiol Biochem 2010;26:761-766.
76. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
77. Nicolay J P, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G Jr, Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232. (Pubitemid 44946977)
78. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol 2003;14:2750-2757. (Pubitemid 37305637)
79. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med 2006;84:378-388. (Pubitemid 43673612)
80. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med 2007;85:273-281.
81. Lang PA, Kasinathan RS, Brand VB, Duranton C, Lang C, Koka S, Shumilina E, Kempe DS, Tanneur V, Akel A, Lang KS, Foller M, Kun JF, Kremsner PG, Wesselborg S, Laufer S, Clemen CS, Herr C, Noegel AA, Wieder T, Gulbins E, Lang F, Huber SM: Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem 2009;24:415-428.
82. Siraskar B, Ballal A, Bobbala D, Foller M, Lang F: Effect of amphotericin B on parasitemia and survival of plasmodium berghei-infected mice. Cell Physiol Biochem 2010;26:347-354.
83. Bobbala D, Alesutan I, Foller M, Huber SM, Lang F: Effect of anandamide in Plasmodium Berghei-infected mice. Cell Physiol Biochem 2010;26:355-362.
84. Foller M, Bobbala D, Koka S, Huber SM, Gulbins E, Lang F: Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem 2009;24:133-140.
85. Koka S, Bobbala D, Lang C, Boini KM, Huber SM, Lang F: Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2009;23:191-198.
86. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006;20:368-370. (Pubitemid 46671174)
87. Birka C, Lang PA, Kempe DS, Hoefling L, Tanneur V, Duranton C, Nammi S, Henke G, Myssina S, Krikov M, Huber SM, Wieder T, Lang F: Enhanced susceptibility to erythrocyte «apoptosis» following phosphate depletion. Pflugers Arch 2004;448:471-477. (Pubitemid 39141524)
88. 2 increases? J Cardiometab Syndr 2008;3:30-34.